ArticleBiomedicines2022

Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment.

Patricia Guerrero-Ochoa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.